ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. (2016)

First Author: Coyle C
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.cct.2016.10.004

PubMed Identifier: 27777129

Publication URI: http://europepmc.org/abstract/MED/27777129

Type: Journal Article/Review

Volume: 51

Parent Publication: Contemporary clinical trials

ISSN: 1551-7144